MedTrace Logo

Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas

NCT00457574 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-08-28

No results posted yet for this study

Summary

GMX1777 is a water-soluble, intravenously-administered prodrug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.

Conditions

  • Solid Tumors and Lymphomas

Interventions

DRUG

GMX1777

Sponsors & Collaborators

  • Gemin X

    lead INDUSTRY

Principal Investigators

  • Mark Berger, MD · Gemin X, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-07-31
Completion
2010-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00457574 on ClinicalTrials.gov